sorafenib has been researched along with deferoxamine in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (deferoxamine) | Trials (deferoxamine) | Recent Studies (post-2010) (deferoxamine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 6,703 | 240 | 1,266 |
| Protein | Taxonomy | sorafenib (IC50) | deferoxamine (IC50) |
|---|---|---|---|
| Lysine-specific demethylase 4A | Homo sapiens (human) | 3.275 | |
| Deoxyhypusine hydroxylase | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC | 1 |
1 review(s) available for sorafenib and deferoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and deferoxamine
| Article | Year |
|---|---|
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Deferoxamine; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Iron Regulatory Protein 2; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Oxidative Stress; Phenylenediamines; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; RNA Interference; Siderophores; Sorafenib | 2013 |